ALISO VIEJO, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the commercial launch of its newest Light Adjustable Lens, the LAL+.

加利福尼亚州ALISO VIEJO，2024年4月4日（环球通讯社）--（纳斯达克：RXST）-RxSight，Inc.，一家致力于为白内障手术后的患者提供高质量定制视力的眼科医疗器械公司，今天宣布其最新可调光镜片LAL+的商业发布。

The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus. In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.

该公司现在在可调光镜头平台上提供两种镜头：LAL®和可调光镜头+™（LAL+）。LAL+具有改进的非球面前表面，可使中央透镜功率持续小幅增加，旨在略微延长聚焦深度。此外，由RxSight Light Adjustable Lens®（LAL/LAL+）、RxSight Light Delivery Device（LDD™）和配件组成的RxSight可调光镜片系统将成为2024年4月5日至8日在波士顿举行的美国白内障和屈光手术学会（ASCRS）年会上各种医生演讲的主题。

At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including: Sunday, April 7, 2024 Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.

在今年的ASCRS会议上，该公司预计将有20多篇关于可调光镜片主题的科学论文、海报和演示文稿，包括：2024年4月7日星期日，使用双脉冲飞秒激光对接受可调光镜片的患者进行弓形切口的好处。

Paper presented by Priya M. Mathews, MD (10:10 a.m. EDT, BCEC, Level 2, 256). Assessing Binocular Vision Post-Implantation with a Newly Approved Light Adjustable Lens with a Modified Aspheric Anterior Surface. Paper presented by T. Hunter Newsom, MD (1:35 p.m. EDT, BCEC, Level 2, 257B). Refractive and Visual Outcomes with a Light Adjustable Lens.

论文由医学博士Priya M.Mathews（美国东部夏令时上午10:10，BCEC，Level 2256）提交。使用新批准的具有改进的非球面前表面的可调光透镜评估植入后的双目视觉。论文由医学博士T.Hunter Newsom（美国东部夏令时下午1:35，BCEC，257B级）提交。光线可调透镜的屈光和视觉效果。

Paper presented by Jonathan M. Davidorf, MD (2:15 p.m. EDT, BCEC, Level 2, 257B). Monday, April 8, 2024 New IOLs to Handle Challenging Cases: LAL. Presentation by Neda Nikpoor, MD (9:05 a.m. EDT, BCEC.

论文由医学博士乔纳森·M·戴维多夫（美国东部夏令时下午2:15，BCEC，257B级）提交。2024年4月8日，星期一，新的人工晶体来处理具有挑战性的病例：LAL。由医学博士内达·尼科普尔（美国东部夏令时上午9:05，BCEC）介绍。